Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29947362 | 1.00 | CYP2A6 (0.39) | CYP2A6IRAK4AURKAMAP3K7FLT3 | |
| SCHEMBL10254559 | 0.75 | IRAK4 (0.40) | IRAK4AURKAMAP3K7FLT3SYK | |
| SCHEMBL30679394 | 0.72 | IRAK4 (0.37) | IRAK4AURKAMAP3K7FLT3SYK | |
| SCHEMBL21371622 | 0.72 | IRAK4 (0.37) | IRAK4AURKAMAP3K7FLT3SYK | |
| SCHEMBL657295 | 0.72 | IRAK4 (0.37) | IRAK4AURKAMAP3K7FLT3SYK | |
| SCHEMBL359942 | 0.71 | SYK (0.39) | CYP2A6SYK | |
| SCHEMBL29936180 | 0.71 | IRAK4 (0.39) | IRAK4AURKAMAP3K7FLT3SYK | |
| SCHEMBL360516 | 0.71 | IRAK4 (0.39) | IRAK4AURKAMAP3K7FLT3SYK | |
| SCHEMBL4302108 | 0.71 | IRAK4 (0.39) | IRAK4AURKAMAP3K7FLT3SYK | |
| SCHEMBL24375572 | 0.70 | IRAK4 (0.39) | IRAK4AURKAMAP3K7FLT3SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102741256-A | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | HANMI PHARM IND CO LTD | 2012-10-17 | — | — | CN | claimed |
| EP-3617213-B1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARMACEUTICAL CO LTD (KR) | 2025-02-19 | — | — | EP | disclosed |
| WO-2022152229-A1 | CLASS OF MORPHOLINE DERIVATIVES, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 深圳微芯生物科技股份有限公司 | 2022-07-21 | — | — | WO | disclosed |
| US-10899772-B2 | IRAK4 modulators | GENENTECH, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| EP-3642201-A1 | ISOINDOLINONE DERIVATIVES AS IRAK4 MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2020-04-29 | — | — | EP | disclosed |
| US-20200115383-A1 | IRAK4 MODULATORS | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| EP-3617213-A1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | Hanmi Pharm. Co., Ltd. (KR) | 2020-03-04 | — | — | EP | disclosed |
| EP-2797927-B1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARM IND CO LTD (KR) | 2019-09-25 | — | — | EP | disclosed |
| US-RE47451-E1 | Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases | HANMI PHARM. CO. LTD. (KR) | 2019-06-25 | — | — | US | disclosed |
| WO-2018234342-A1 | ISOINDOLINONE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-12-27 | — | — | WO | disclosed |
| US-20140303149-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2014-10-09 | — | — | US | disclosed |
| WO-2013100632-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARM CO., LTD. (KR) | 2013-07-04 | — | — | WO | disclosed |
| EP-2593457-A1 | PYRAZOLO [1, 5A]PYRIMIDINE AND THIENO [3, 2B]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| CN-102985426-A | Pyrazolo [1, 5A ] pyrimidine and thieno [3, 2B ] pyrimidine derivatives as IRAK4 modulators | HOFFMANN LA ROCHE | 2013-03-20 | — | — | CN | disclosed |
| CN-102741256-A | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | HANMI PHARM IND CO LTD | 2012-10-17 | — | — | CN | disclosed |
| CN-102725296-A | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases | HANMI SCIENCE CO LTD (KR) | 2012-10-10 | — | — | CN | disclosed |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | ARORA NIDHI (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | ARORA NIDHI (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2012007375-A1 | PYRAZOLO [1, 5A] PYRIMIDINE AND THIENO [3, 2B] PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007375-A1 | PYRAZOLO [1, 5A] PYRIMIDINE AND THIENO [3, 2B] PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303149-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | CYP2A6 3463/4885IRAK4 1/4885AURKA 917/4885 |
| US-20200115383-A1 | IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | CYP2A6 3299/4885IRAK4 1/4885AURKA 456/4885 |
| US-10899772-B2 | IRAK4 modulators | IRAK4, IRAK1, IRAK2 | CYP2A6 3299/4885IRAK4 1/4885AURKA 456/4885 |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | CYP2A6 3463/4885IRAK4 1/4885AURKA 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.